Cabozantinib is a kinase inhibitor, which exerts anti-tumor effects by inhibiting the activity of various kinases in the body, and can delay tumor progression and metastasis, and inhibit tumor neovascularization. It is mostly used in the treatment of progressive, unresectable locally advanced or metastatic medullary thyroid cancer; advanced renal cancer with sunitinib treatment failure; advanced non-small cell lung cancer patients with C-met amplification; hepatocellular carcinoma patients with sorafenib resistance; advanced prostate cancer patients with bone metastasis. It should be noted that the use of this drug is prohibited for those who are allergic to any component of this drug. Some patients may experience adverse reactions such as diarrhea, fatigue, nausea, loss of appetite, hypertension, constipation and so on after using the drug, and in serious cases, it may also cause adverse reactions such as bleeding, gastrointestinal perforation and fistula, thrombotic events and so on, and they should consult a doctor in time. Drugs need to be used under the guidance of a doctor, not blindly on their own, so as not to affect the condition, or to induce adverse reactions.